Proactive Investors - Run By Investors For Investors

ReNeuron provides further encouraging update for potential sight-saving treatment

"We remain greatly encouraged by the continued positive efficacy we are seeing," said chief executive Olav Hellebø
eye chart
The latest group to be treated with human retinal progenitor cells comprises patients who have a greater baseline level of visual acuity (clarity of vision) than those taking part in the clinical assessment thus far

ReNeuron Group PLC (LON:RENE) shares leapt higher on Thursday after the group said its cell therapy for blindness-causing disease retinitis pigmentosa is proving efficacious in the first group of phase II patients receiving the treatment.

This follows from February’s update from which it emerged that the first three people taking part in the phase I/II study were able to read an additional three lines of a standard eye chart.

READ: ReNeuron starts dosing second cohort in eye disease trial

The latest group to be treated with human retinal progenitor cells (hRPCs) comprises patients who have a greater baseline level of visual acuity (clarity of vision) than those taking part in the clinical assessment thus far.

Further data from the trial will be shared at the Sixth Annual Retinal Cell and Gene Therapy Innovation Summit, in Vancouver, Canada, later this month.

"We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing phase I/II study with our hRPC cell therapy candidate for retinitis pigmentosa,” said ReNeuron chief executive Olav Hellebø.

“We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month."

In mid-morning trading, ReNeuron shares soared 17% higher to 142p.

 -- Adds share price --

 

View full RENE profile View Profile

ReNeuron Group PLC Timeline

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use